Literature DB >> 28406730

Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Alok A Khorana1, Pamela B Mangu1, Matthew H G Katz1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28406730     DOI： 10.1200/JOP.2017.023044

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  7 in total

Review 1.  Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy.

Authors:  Reetesh K Pai; Rish K Pai
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

Review 3.  Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology.

Authors:  Catherine M Sielaff; Shaker A Mousa
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-02       Impact factor: 4.553

4.  Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.

Authors:  N O Elander; K Aughton; P Ghaneh; J P Neoptolemos; D H Palmer; T F Cox; F Campbell; E Costello; C M Halloran; J R Mackey; A G Scarfe; J W Valle; A C McDonald; R Carter; N C Tebbutt; D Goldstein; J Shannon; C Dervenis; B Glimelius; M Deakin; R M Charnley; A Anthoney; M M Lerch; J Mayerle; A Oláh; M W Büchler; W Greenhalf
Journal:  Br J Cancer       Date:  2018-03-09       Impact factor: 7.640

5.  MiR-10b inhibits migration and invasion of pancreatic ductal adenocarcinoma via regulating E2F7.

Authors:  Cui Xu; Xiangxiu Qi
Journal:  J Clin Lab Anal       Date:  2020-06-26       Impact factor: 2.352

6.  EUS-guided solid pancreatic tumor ablation.

Authors:  Emanuele Dabizzi; Paolo Giorgio Arcidiacono
Journal:  Endosc Ultrasound       Date:  2017-12       Impact factor: 5.628

7.  Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.

Authors:  Lukuan You; Jinliang Wang; Fan Zhang; Jing Zhang; Haitao Tao; Xuan Zheng; Yi Hu
Journal:  Mol Med Rep       Date:  2018-11-19       Impact factor: 2.952
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.